April McCulloh, MD
Family Medicine · Denham Springs, LANPI 1114160702
Payments from drug & device makers
Across 507 payments — averaging $48.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$18K
- Novo Nordisk$1K
- GSK$941
- Amgen$584
- Takeda Pharmaceuticals U.S.A., Inc.$512
- Lilly USA, LLC$417
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$16,53867%
- Food & beverage$7,99532%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 129 | $18,239 |
| Novo Nordisk | 70 | $1,091 |
| GSK | 66 | $941 |
| Amgen | 41 | $584 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $512 |
| Lilly USA, LLC | 25 | $417 |
| AstraZeneca | 18 | $281 |
| Pfizer | 16 | $279 |
| Boehringer Ingelheim | 14 | $232 |
| Astellas Pharma US Inc | 6 | $192 |
| Novartis | 9 | $189 |
| Abbott | 8 | $184 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $163 |
| Bayer | 8 | $149 |
| Merck | 8 | $142 |
| Axsome Therapeutics, Inc. | 6 | $128 |
| Exact Sciences | 7 | $125 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $115 |
| Amarin Pharma, Inc. | 6 | $114 |
| Sanofi-aventis U.S. LLC | 7 | $99 |
| Kowa Pharmaceuticals America, Inc. | 5 | $84 |
| Eisai Inc. | 4 | $80 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Johnson & Johnson | 2 | $37 |
| Neurocrine Biosciences, Inc. | 1 | $31 |
| Boston Scientific | 1 | $23 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Amneal Pharmaceuticals LLC | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Agile Therapeutics, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,631 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 141 | $173,476 |
| JardianceEmpagliflozin | 83 | $99,701 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $87,736 |
| OzempicSemaglutide | 55 | $69,166 |
| TrulicityDulaglutide | 27 | $38,337 |
| FarxigaDapagliflozin Propanediol | 33 | $30,663 |
| JanuviaSitagliptin Phosphate | 23 | $24,274 |
| LinzessLinaclotide | 39 | $23,303 |
| VraylarCariprazine Hcl | 16 | $22,930 |
| VascepaIcosapent Ethyl | 32 | $22,852 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 12 | $20,749 |
| Repatha SyringeEvolocumab | 14 | $17,466 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 19 | $14,419 |
| TradjentaLinagliptin | 11 | $12,759 |
| GlyxambiEmpagliflozin/Linagliptin | 18 | $10,532 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $417 | $211,813168 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta, Glyxambi | $232 | $137,412131 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $941 | $94,87090 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $1,091 | $89,91567 claims |
| AbbVieLinzess, Vraylar, Synthroid | $18,239 | $49,82098 claims |
| AstraZenecaFarxiga | $281 | $30,66333 claims |
| MerckJanuvia | $142 | $24,27423 claims |
| Astellas Pharma US IncMyrbetriq | $192 | $7,25517 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $21 | $2,619370 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Denham Springs
- Durwin WalkerDenham Springs$16K
- Patrick WalkerDenham Springs$15K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.